Survival and Hematologic Benefits of Romiplostim After Acute Radiation Exposure Supported FDA Approval Under the Animal Rule

Deborah I. Bunin,Harold S. Javitz,Janet Gahagen,James Bakke, Joan H. Lane, Dina A. Andrews,Polly Y. Chang

International journal of radiation oncology, biology, physics（2023）

引用 2|浏览4

暂无评分

摘要

These results were pivotal in obtaining FDA-approval in January 2021 for romiplostim's new indication as a single administration therapy to increase survival in adults and pediatric patients acutely exposed to myelosuppressive doses of radiation.

查看译文

关键词

acute radiation exposure,romiplostim,radiation exposure,hematologic benefits

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要